THANK YOU FOR SUBSCRIBING
Atriva Therapeutics aims to develop a therapy platform to treat severe respiratory diseases induced by RNA viruses with a high unmet medical need, such as influenza and COVID-19
FREMONT, CA: Atriva Therapeutics, a Germany-based biopharmaceutical company developing host-targeting antiviral therapies, closed a €8.6m convertible loan, led by Meneldor B.V. and High-Tech Gründerfonds (HTGF), and joined by existing shareholders and new German and international investors.
The capital from the transaction will allow Atriva to start a multinational, double-blind, randomized clinical Phase II study in patients with moderate to severe COVID-19 infections, once authorization is granted by the German Federal Institute for Drugs and Medical Devices (Bundesinstitutfür Arzneimittel und Medizinprodukte, BfArM). It will further be used to prepare a Phase II trial in influenza and to continue building a therapy platform to treat respiratory diseases induced by RNA viruses, such as Hantavirus.
Stay ahead of the industry with exclusive feature stories on the top companies, expert insights and the latest news delivered straight to your inbox. Subscribe today.
Founded in 2015 by Dr. Rainer Lichtenberger, CEO, Atriva Therapeutics is a biopharmaceutical company pioneering the development of host-targeting antiviral therapies. Its lead product ATR-002 is a host-targeting agent which inhibits viral replication in influenza and favorably modulates the body’s immune response.
“With such highly committed investors continuing to support our plans we will now focus on ramping-up this important pivotal Phase II trial to treat patients with moderate to severe COVID-19,” said Dr. Rainer Lichtenberger, co-founder, and CEO of Atriva. “This transaction is connected to additional ongoing financing activities which will support Atriva all the way through completion of two Phase II programs in COVID-19 and influenza.”
ATR-002 is under clinical development and has successfully completed a Phase I trial to demonstrate safety and tolerability in healthy subjects. A Phase II study to evaluate efficacy in hospitalized COVID-19 patients is in preparation; a Phase II study in influenza is planned to start in early 2021.
The company owns eleven patent families with broad international coverage related to the use of MEK inhibitors and other kinase inhibitors for antiviral therapies, and the patent life runs through 2041.
More in News